Standard NIPT does not test for Noonan syndrome. The routine NIPT offered during most pregnancies screens for chromosomal conditions like Down syndrome (trisomy 21), trisomy 18, and trisomy 13. Noonan syndrome is caused by mutations in individual genes, not by extra or missing chromosomes, so it falls outside what standard NIPT detects. However, a newer, expanded form of NIPT designed for single-gene disorders can screen for Noonan syndrome, and it’s available from some labs starting at 9 weeks of pregnancy.
Why Standard NIPT Misses Noonan Syndrome
Standard NIPT works by analyzing fragments of fetal DNA circulating in the mother’s blood and counting chromosomes. It’s excellent at detecting conditions where there’s an entire extra chromosome, like trisomy 21. Noonan syndrome is fundamentally different. It’s caused by a small mutation within a single gene, most commonly one called PTPN11, though at least 16 other genes in the same biological pathway can also be responsible. Counting chromosomes won’t reveal these tiny spelling errors in the genetic code, which is why Noonan syndrome doesn’t show up on standard screening.
Expanded NIPT for Single-Gene Disorders
A newer category of testing, sometimes called NIPT for single-gene disorders (NIPT-SGD), takes a different approach. Instead of counting chromosomes, it sequences specific genes in the fetal DNA fragments found in maternal blood. Early clinical panels have focused on a set of about 30 genes linked to 25 dominant conditions, and Noonan spectrum disorders are among them.
This type of screening can be performed as early as 9 weeks of pregnancy using a maternal blood draw, plus a blood or saliva sample from the father to help distinguish fetal mutations from inherited variants. It’s not part of routine prenatal care, though. Expanded NIPT-SGD is typically offered through specialized labs, and availability varies by provider and region. Labcorp, for example, lists a fetal Noonan syndrome analysis among its testing options.
What Triggers Noonan Screening During Pregnancy
In practice, prenatal testing for Noonan syndrome is most often prompted by something unusual on ultrasound rather than by a routine screening panel. The two most common red flags are increased nuchal translucency (a thick fluid collection at the back of the baby’s neck, measured in the first trimester) and cystic hygroma, a fluid-filled mass in the neck area. In one study of pregnancies referred for Noonan gene testing, 44% had increased nuchal translucency and 48% had cystic hygroma as the primary reason for referral.
Other ultrasound findings that raise suspicion include excess amniotic fluid (polyhydramnios), fluid accumulation around the baby’s organs (hydrops fetalis), pleural effusion around the lungs, heart defects, kidney abnormalities, and swollen lymphatic sacs in the neck. The pattern that most reliably points toward Noonan syndrome is increased nuchal translucency combined with at least one of these additional features. When multiple signs appear together, clinicians are more likely to recommend targeted genetic testing.
Screening vs. Diagnostic Testing
Even expanded NIPT-SGD is a screening test, not a diagnosis. A positive result means there’s an elevated chance the baby has a mutation associated with Noonan syndrome, but it doesn’t confirm it. False positives can occur because the test is reading short fragments of DNA in the mother’s blood, and distinguishing a true fetal mutation from background noise is technically challenging at this scale.
If NIPT-SGD flags a possible Noonan-related mutation, the next step is a diagnostic procedure like chorionic villus sampling (CVS) or amniocentesis. These collect fetal cells directly, allowing labs to sequence the baby’s DNA with much higher accuracy. Diagnostic testing can examine the full set of genes linked to Noonan syndrome. Current panels cover 17 genes, including PTPN11, SOS1, RAF1, KRAS, BRAF, RIT1, and others in the same signaling pathway.
What Noonan Syndrome Genes Are Tested
Noonan syndrome isn’t caused by a single gene. It belongs to a group of related conditions called RASopathies, all involving genes in a cell-signaling pathway that controls growth and development. A comprehensive Noonan panel typically covers 17 genes: PTPN11, SOS1, SOS2, RAF1, KRAS, BRAF, HRAS, NRAS, MAP2K1, MAP2K2, MAPK1, RIT1, RRAS2, CBL, LZTR1, SHOC2, and NF1. PTPN11 accounts for roughly half of all Noonan cases, making it the single most important gene on the panel. SOS1 and RAF1 are the next most common.
Expanded NIPT panels don’t necessarily cover all 17 genes. The early clinical versions screened a broader set of 30 genes across 25 conditions, but the specific Noonan genes included can vary by lab. If you’re considering this type of screening, it’s worth confirming exactly which genes the panel covers, especially if there’s a family history involving a known mutation.
Practical Considerations
Expanded NIPT-SGD requires both a maternal blood sample and a paternal sample (blood or saliva). The paternal sample isn’t optional. It helps the lab identify which DNA variants the baby inherited normally from each parent and which, if any, arose as new (de novo) mutations. Most Noonan syndrome cases are de novo, meaning neither parent carries the mutation, which makes the paternal comparison essential for interpretation.
Cost and insurance coverage for expanded NIPT vary widely. Standard NIPT for trisomies is now covered by many insurance plans, but single-gene screening is newer and less consistently reimbursed. Some labs offer self-pay pricing, and genetic counselors can help navigate both the financial and medical decision-making involved. If your ultrasound has shown concerning findings like increased nuchal translucency or cystic hygroma, the clinical case for targeted testing is stronger, and coverage may be more straightforward.